Senzime granted US Patent for OnZurf Probe


 

The OnZurf Probe was acquired by Senzime in 2016 and is based on an innovation by Dr. Pernilla Abrahamsson and clinical research at Umeå University. The development, including CE approval of OnZurf, was completed by Senzime in 2017. The probe is designed to enable continuous sampling from gastro-intestinal organs such as esophagus, stomach and liver. By monitoring the organ surface, it is possible to detect elevations in lactate and other metabolic markers as early indicators of ischemia and post-operative complications.

As of November 2020, Senzime has out licensed the OnZurf probe for the European market transferring the legal manufacturing rights and all related product liabilities to the company Moss S.p.A based outside Milano, Italy. Senzime has retained the rights to commercialization of OnZurf on all markets outside of Europe, including the US.

”OnZurf Probe is a unique product with a huge potential for early detection of serious conditions such as ischemia. This US patent will be very important in future commercialization of OnZurf on the US market”, says Pia Renaudin, CEO of Senzime.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com

       

TO THE EDITORS
About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com 

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on December 23, 2020, 16:15 CET.